Gabapentinoids Linked to Increased Risk for Severe Exacerbation in COPD
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 16, 2024 -- Gabapentinoid use is associated with an increased risk for severe exacerbation among patients with chronic obstructive pulmonary disease (COPD), according to a study published online Jan. 16 in the Annals of Internal Medicine.
Alvi A. Rahman, from McGill University in Montreal, Quebec, Canada, and colleagues examined whether gabapentinoid use is associated with severe exacerbation in patients with COPD in a propensity score-matched, new-user cohort study. Within a base cohort of COPD patients, those initiating gabapentinoid therapy with an indication were matched with nonusers. The cohort included 356 gabapentinoid users with epilepsy, 9,411 with neuropathic pain, and 3,737 with other chronic pain who were matched to nonusers in a 1:1 ratio.
The researchers found that gabapentinoid use was associated with an increased risk for severe COPD exacerbations compared with nonuse overall (hazard ratio, 1.39) and across the indications of epilepsy, neuropathic pain, and other chronic pain (hazard ratios, 1.58, 1.35, and 1.49, respectively).
"These findings support the warnings from regulatory agencies and highlight the importance of considering this potential risk when prescribing gabapentin and pregabalin to patients with COPD," the authors write.
The study was partially supported by a grant from Boehringer Ingelheim.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
TUESDAY, May 21, 2024 -- The use of race-based and race-neutral equations for lung-function testing generate similarly accurate predictions of respiratory outcomes, but differ in...
Pulmonologist Intervention Beneficial for Undiagnosed Asthma, COPD
TUESDAY, May 21, 2024 -- For adults with undiagnosed asthma and chronic obstructive pulmonary disease (COPD), receipt of pulmonologist-directed treatment is associated with less...
Dupilumab Tied to Fewer Exacerbations in COPD With Type 2 Inflammation
TUESDAY, May 21, 2024 -- Dupilumab is associated with fewer exacerbations for patients with chronic obstructive pulmonary disease (COPD) with type 2 inflammation, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.